SLC5A2 and type 2 diabetes mellitus: Another prospective longitudinal study developed in a tertiary care center in India that included 80 patients with type 2 diabetes who started the treatment with SGLT2 inhibitors aimed to evaluate the prevalence of genital and urinary tract infections at baseline and after 12 weeks from the initiation.